MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial
2017
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
20
Citations
NaN
KQI